Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
      By: Menéndez, Alvarado S.B. No. 1525     A BILL TO BE ENTITLED   AN ACT   relating to prior authorization for prescription drug benefits   related to the treatment of neurodegenerative diseases.          BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:          SECTION 1.  The heading to Subchapter N, Chapter 1369,   Insurance Code, is amended to read as follows:   SUBCHAPTER N.  COVERAGE OF PRESCRIPTION DRUGS FOR AUTOIMMUNE AND   NEURODEGENERATIVE  DISEASES AND CERTAIN BLOOD DISORDERS          SECTION 2.  Section 1369.654, Insurance Code, is amended by   amending Subsection (a) and adding Subsection (c) to read as   follows:          (a)  A health benefit plan issuer that provides prescription   drug benefits may not require an enrollee to receive more than one   prior authorization annually of the prescription drug benefit for a   prescription drug prescribed to treat an autoimmune disease, a   neurodegenerative disease,  hemophilia, or Von Willebrand disease.           (c)     Notwithstanding Subsection (a), a health benefit plan   issuer may require an enrollee who is prescribed a new prescription   drug to treat a neurodegenerative disease to obtain a prior   authorization for the prescription drug.          SECTION 3.  The change in law made by this Act applies only   to a health benefit plan that is delivered, issued for delivery, or   renewed on or after January 1, 2026.  A health benefit plan   delivered, issued for delivery, or renewed before January 1, 2026,   is governed by the law as it existed immediately before the   effective date of this Act, and that law is continued in effect for   that purpose.          SECTION 4.  This Act takes effect September 1, 2025.